STOCK TITAN

Acrivon Therapeutics EVP plans sale of 504 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. co-founder and EVP Dr. Kristina Masson, identified as an officer and director, reported a planned sale of 504 common shares on November 17, 2026, with an aggregate market value of $720.72. She acquired 1,670 shares on November 14, 2026, through settlement of vested RSUs issued under an S-8 Registration Plan; the stated sale mechanics are automatic sales to satisfy mandatory tax withholding upon vesting.

Common shares planned for sale 504 shares Approximate sale date November 17, 2026
Aggregate market value $720.72 For the planned sale of 504 common shares
Shares acquired through RSU settlement 1,670 shares November 14, 2026
Common shares outstanding 42,911,680 shares Acrivon common shares outstanding, as listed
RSUs financial
"Settlement of vested RSUs issued under an S-8 Registration Plan"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
S-8 Registration Plan regulatory
"issued under an S-8 Registration Plan"
mandatory tax withholding requirement financial
"satisfy the mandatory tax withholding requirement upon vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ACRV shares does Kristina Masson plan to sell?

Kristina Masson reported a planned sale of 504 Acrivon common shares, with an aggregate market value of $720.72 and an approximate sale date of November 17, 2026. The stated sale mechanics are automatic sales to satisfy mandatory tax withholding upon vesting of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading